Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-07-11
2006-07-11
Epps-Ford, Janet L. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500, C435S325000, C435S375000
Reexamination Certificate
active
07074768
ABSTRACT:
Disclosed are synthetic, modified oligonucleotides complementary to, and capable of down-regulating the expression of, nucleic acid encoding protein kinase A subunit RIα. The modified oligonucleotides have from about 15 to about 30 nucleotides and are hybrid, inverted hybrid, or inverted chimeric oligonucleotides. Also disclosed are therapeutic compositions containing such oligonucleotides and methods of using the same. In addition, therapeutic compositions and methods of their use are described which are directed to a synergistic effect resulting from the combination of oligonucleotides of the invention and other therapeutic compositions and methods.
REFERENCES:
patent: 4309404 (1982-01-01), DeNeale et al.
patent: 4309406 (1982-01-01), Guley et al.
patent: 4556552 (1985-12-01), Porter et al.
patent: 4704295 (1987-11-01), Porter et al.
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5149797 (1992-09-01), Pederson et al.
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5271941 (1993-12-01), Cho-Chung
patent: 5447936 (1995-09-01), Hausheer et al.
patent: 5470967 (1995-11-01), Huie et al.
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5658947 (1997-08-01), DasGupta et al.
patent: 5969117 (1999-10-01), Agrawal
patent: 6608035 (2003-08-01), Agrawal et al.
patent: 6624293 (2003-09-01), Agrawal
patent: 41 10 085 (1992-10-01), None
patent: 0 490 077 (1991-10-01), None
patent: WO 91/12323 (1991-08-01), None
patent: WO 93/13114 (1993-07-01), None
patent: WO 93/13121 (1993-07-01), None
patent: WO 93/13740 (1993-07-01), None
patent: WO 94/02498 (1994-02-01), None
patent: WO 94/02499 (1994-02-01), None
patent: WO 94/07367 (1994-04-01), None
patent: WO 94/08003 (1994-04-01), None
patent: WO 94/13685 (1994-06-01), None
patent: 94/17189 (1994-08-01), None
patent: 94/23028 (1994-10-01), None
patent: WO 94/26887 (1994-11-01), None
patent: WO 95/02069 (1995-01-01), None
patent: WO 95/09236 (1995-04-01), None
patent: 95/15378 (1995-06-01), None
patent: 96/16976 (1996-06-01), None
patent: 96/31600 (1996-10-01), None
patent: 97/11171 (1997-03-01), None
Andrea D. Branch, A good antisense molecule is hard to find, TIBS, 47-48, Feb. 1998.
Stanley Crooke, Antisense Research and Applications, Chapter 1, Basic Principles of Antisense Therapeutics, Springer-Verlag Press, Berlin, Heidelberg, New York, p. 3, Jul. 1998.
Tortora et al. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A, Nov. 1997.
Kathleen McGowan, Feature: Nothing to Fear But Fear Itself: How FDA and Pharma Will Make Microarrays Mainstream. Genomeweb.com—View Article, Apr. 16, 2002, pp. 1-2.
Prewett et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. Nov. 1996, Journal of Immunotherapy with emphasis on tumor immunology: official journal of the Society for Biological Therapy. vol. 19(6), pp. 419-427. (see abstract).
Clair et al., “An antisense oligodeoxynucleotide targeted against the type I regulatory subunit (RIα) mRNA of cAMP-dependent protein kinase (PKA) inhibits the growth of LS-174T human colon carcinoma in athymic mice”,Proc. AACR, 32, 277, Abstract #1645 (1991).
Folkman, Judah, “Tumor Angiogensis.” In: J. Mendelsohn et al., eds.,The Molecular Basis of Cancer, pp. 206-232, Philadelphia: WB Saunders (1995).
Goodchild, John, “Bioconjugate Chemistry”Bioconjugate Chem., vol. 1, pp. 165-187 (1990).
Iversen, Antisense Research and Application (Crooke, ed) CRC Press, pp. 461-469 (1993).
Kabat and Mayer (eds),Experimental Immunochemistry, 2d Ed., Springfield, IL, CC Thomas, p. 125.
Rohlff et al., “8-Cl-cAMP induces truncation and down-regulation of the RI alpha subunit and up-regulation of the RII beta subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells.”J. Biol. Chem., vol. 268, pp. 5774-5782 (1993).
Slapak et al. in Harrison's Principles of Internal Medicine (Isselbacher et al., eds.) McGraw-Hill, Inc., NY, pp. 1826-1850 (1994).
Uhler et al. “Expression of cDNAs for two isoforms of the catalytic subunit of cAMP-dependent protein kinase.”J. Biol. Chem., vol. 262, pp. 15202-15207 (1987).
Uhlmann and Peyman, “Antisense Oligonucleotides: A New Therapeutic Principle.”Chem. Rev., vol. 90, pp. 544-584 (1990).
Zhang et al., “In Vivo Statbility, Disposition and Metabolism of a “Hybrid” Oligonucleotide Phosphorothioate in Rats”Biochemical Pharmacology, vol. 50, pp. 545-556 (1995).
Agrawal and Goodchild, “Oligodeoxynucleodise Methylphosphonates: Synthesis and Enzymic Degradation.”Tet. Lett., vol. 28, No. 31, pp. 3539-3542 (1987).
Agrawal and Zhang, “Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animal” In: Antisense Research and Application, S. T. Crooke, ed., Handbook of Experimental Pharmacology, Springer, Berlin, pp. 525-543 (1998).
Agrawal et al., “Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.”Proc. Natl. Acad. Sci.(USA), vol. 85, pp. 7079-7083 (1988).
Agrawal et al., “Antisense oligonucleotides as antiviral agents.”Trends Biotechnol., vol. 10, pp. 152-158 (1992).
Beaucage, Serge L., “Oligodeoxyribonucleotides Synthesis in Protocols for Oligonucleotide Analogs,”Meth. Mol. Biol., vol. 20, pp. 33-61 (1993) Humana Press, Totowa, NJ.
Beebe et al. “Cyclic Nucleotides-Dependent Protein Kinases” in The Enzymes: Control by Phosphorylation, Academic Press, NY, vol. 17, No. A, pp. 43-111 (1986).
Bergot et al. “Separation of synthetic phoshorothioate oligodeoxynucleotides from their oxygenated (phosphodiester) defect species by strong-anion-exchange high-performance liquid chromatography.”J. Chromatog., vol. 559, pp. 35-42 (1992).
Buckheit et al, “Characterization of an HIV-1 Isolated Displaying an Apparent Absence of Virion-Associated Reverse Transcriptase Activity.”AIDS Research and Human Retroviruses, vol. 7, No. 3, pp. 295-302 (1991).
Cadd et al., “Holoenzymes of cAMP-dependent protein kinase containing the neural form of type I regulatory subunit have an increased sensitivity to cyclic nucleotides.”J. Biol. Chem., vol. 265, pp. 19502-19506 (1990).
Cambell et al., “Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid.”Biochem. Biophys. Meth., vol. 20, pp. 259-267 (1990).
Cheng et al., “An active twenty-amino-acid-residue peptide derived from the inhibitor protein of the cyclic AMP-dependent protein kinase.”Biochem J., vol. 231, No. 3, pp. 655-661 (1985).
Cho-Chung, YS, “Hypothesis. Cyclic AMP and its receptor protein in tumor growth regulation in vivo.”J. Cyclic Nucleotide Res., vol. 6, pp. 163-167 (1980).
Cho-Chung, YS, “Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy.”Cancer Res., vol. 50, pp. 7093-7100 (1990).
Cho-Chung et al.,Curr. Opin. Thera. Patents, vol. 3, pp. 1737-1750 (1993).
Ciardiello and Tortora, “Interactions between the Epidermal Growth Factor Receptor and Type I Protein Kinase A: Biological Significance and Therapeutic Implications.”Clin. Cancer Res., vol. 4, pp. 821-828 (1998).
Clegg et al., “Genetic characterization of a brain-specific form of the type I regulatory subunit of cAMP-dependent protein kinase”Proc. Natl. Acad. Sci.(USA), vol. 85, pp. 3703-3707 (1988).
Ekanager et al., “The Seprate Estimation of cAMP Intracellularly Bound to the Regulatory Subunits of Protein Kinase I and II in Glucagon-stimulated Rat Hepatocytes.”J. Biol. Chem, vol. 260, pp. 3393-3401 (1985).
Froehler, Brian C., “Deoxynucleoside H-Phosphonate Diester Intermediates in the
Epps-Ford Janet L.
Idera Pharmaceuticals Inc.
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Modified protein kinase A-specific oligonucleotides and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified protein kinase A-specific oligonucleotides and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified protein kinase A-specific oligonucleotides and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3539032